�
Small, specially designed bits of ribonucleic acid (RNA) can interfere with cholesterin metabolism, reducing harmful cholesterol by two-thirds in preclinical tests, according to a new survey by researchers at UT Southwestern Medical Center in collaboration with Alnylam Pharmaceuticals and the Massachusetts Institute of Technology.
In a study that appears online today and in an upcoming issue of the Proceedings of the National Academy of Sciences, researchers found that a single
